Clinical Trials
84 trialsNCT02184416 2026-02-27
ADONIS
Pfizer
Completed
NCT06690697 2024-11-15
Combination of Toripalimab and JS004 Therapy for ccRCC
Fudan University
Phase 2 Recruiting
NCT00606866 2023-11-29
MRI
University of Chicago
Phase 3 Completed
NCT00496756 2023-10-26
Sorafenib in Treating Patients With Metastatic or Unresectable Kidney Cancer
University of Nebraska
Phase 2 Terminated
NCT02627963 2023-07-18
A Study to Compare Tivozanib Hydrochloride to Sorafenib in Participants With Refractory Advanced Renal Cell Carcinoma (RCC)
AVEO Pharmaceuticals, Inc.
Phase 3 Completed
NCT01664182 2022-06-07
Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00326898 2022-02-08
ASSURE
National Cancer Institute (NCI)
Phase 3 Completed
NCT01444807 2021-09-17
Evaluate the Efficacy of Sorafenib in Renal Cell Carcinoma Patients After a Radical Resection of the Metastases
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 2 Unknown
NCT00121251 2021-04-06
Sorafenib, Gemcitabine, and Capecitabine in Treating Patients With Unresectable and/or Metastatic Kidney Cancer
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT02187302 2020-05-28
CRLX101(NLG207) in Combination With Bevacizumab for Metastatic Renal Cell Carcinoma (mRCC) Versus Standard of Care (SOC)
Lumos Pharma
Phase 2 Completed
NCT02406521 2020-03-04
Exploratory Study of Radium-223 and VEGF-Targeted Therapy in Patients With Metastatic Renal Cell Carcinoma and Bone Mets
Dana-Farber Cancer Institute
Phase 1 Completed
NCT01497444 2020-02-06
Sorafenib Tosylate and Hypoxia-Activated Prodrug TH-302 in Treating Patients With Advanced Kidney Cancer or Liver Cancer That Cannot Be Removed By Surgery
Alliance for Clinical Trials in Oncology
Phase 1 Completed
NCT01195649 2019-06-04
Advanced Renal Cell Carcinoma, With Failure or Unsuitable on Prior Interferon-alpha or Interleukin-2 Based Therapy
Bayer
Terminated
NCT00727532 2019-05-03
Sorafenib in Treating Patients With Locally Advanced or Metastatic Kidney Cancer
Northwestern University
Phase NA Terminated
NCT01731158 2019-02-06
BERAT
Central European Society for Anticancer Drug Research
Phase 2 Completed
NCT00126659 2018-11-20
Sorafenib in Treating Patients Who Are Undergoing Surgery for Metastatic Kidney Cancer
National Cancer Institute (NCI)
Phase 2 Terminated
NCT01762150 2018-11-20
Sorafenib Combined With Chemotherapy for Renal Collecting Duct Carcinoma
Peking University Cancer Hospital & Institute
Phase 2 Completed
NCT00378703 2018-11-14
Bevacizumab, Sorafenib Tosylate, and Temsirolimus in Treating Patients With Metastatic Kidney Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT02560012 2018-10-12
Personalized Targeted Inhibitors Treatment in Renal Cell Cancer
The University of Texas Health Science Center, Houston
Phase 2 Terminated
NCT01411423 2018-06-06
Nexavar Post-marketing Surveillance for Renal Cell Carcinoma in Japan
Bayer
Completed
NCT01412671 2018-06-06
Nexavar Post-marketing Surveillance for RCC in Japan: Early Access Program
Bayer
Completed
NCT03456401 2018-03-07
TOKIO
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 2 Terminated
NCT01982097 2018-02-07
SANE
Bayer
Completed
NCT02122003 2017-11-22
SOAP
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 2 Terminated
NCT01728948 2017-11-09
Sorafenib in Elderly mRCC
Bayer
Completed
NCT01189370 2017-06-01
Evaluate Safety and Tolerability in Dose Escalation of Sorafenib in Advanced Renal Cell Cancer
University of Kansas Medical Center
Phase 2 Completed
NCT02330783 2017-05-09
Efficacy and Safety of Bevacizumab Plus Sorafenib for the Third-line Treatment in Metastatic Renal Cancer Patients
Peking University Cancer Hospital & Institute
Phase 2 Unknown
NCT00405366 2017-04-18
NRR
UNC Lineberger Comprehensive Cancer Center
Phase EARLY_PHASE1 Completed
NCT01557127 2017-03-28
NEXST
Bayer
Completed
NCT00126594 2016-09-16
Sorafenib Tosylate With or Without Recombinant Interferon Alfa-2b in Treating Patients With Metastatic Kidney Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT01183663 2016-06-03
Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)
M.D. Anderson Cancer Center
Phase 1 Completed
NCT00467025 2016-03-23
AMG 386, 20060159 Phase 2, RCC 1st Line in Combination With Sorafenib
Amgen
Phase 2 Completed
NCT00445042 2016-03-17
Safety and Toxicity Study of Sorafenib in Patients With Kidney Cancer
The Methodist Hospital Research Institute
Phase 2 Completed
NCT00448149 2016-03-17
Phase I/II Trial of RAD001 Plus Nexavar in Patients With Kidney Cancer
The Methodist Hospital Research Institute
Phase 1/2 Completed
NCT00618982 2015-12-24
Sorafenib Dose Escalation in Renal Cell Carcinoma
Bayer
Phase 2 Completed
NCT00480389 2015-12-09
Pre-operative Administration of Sorafenib in Patients With Metastatic Renal Cell Carcinoma Undergoing Kidney Removal
University Health Network, Toronto
Phase 2 Completed
NCT01223027 2015-12-07
Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma
Novartis
Phase 3 Completed
NCT01342627 2015-10-06
SERCC
Centro di Riferimento Oncologico - Aviano
Phase 2 Terminated
NCT01012011 2015-09-21
Regulatory Post Marketing Surveillance Study on Nexavar®
Bayer
Completed
NCT01100242 2015-09-17
Velcade and Sorafenib in Unresected or Metastatic Renal Cell Carcinoma
New Mexico Cancer Research Alliance
Phase 2 Terminated
NCT00609934 2015-07-23
Study of Sorafenib and Palliative Radiotherapy in Kidney Cancer That Spreads to the Bone
University Health Network, Toronto
Phase 1/2 Completed
NCT00854620 2015-06-19
Safety and Toxicity Study of Sorafenib in Patients With Kidney Cancer
Stanford University
Phase 2 Completed
NCT00589550 2015-06-08
PEG-Interferon Alfa-2b and Sorafenib in Treating Patients With Unresectable or Metastatic Kidney Cancer
Ohio State University Comprehensive Cancer Center
Phase 1 Terminated
NCT01507740 2015-04-29
Profile of Soluble and Cellular Biomarkers and of Functional Imaging During Antiangiogenic Therapies in Cancer Patients
Medical University Innsbruck
Terminated
NCT01353794 2015-01-30
POWER-NEXT
Bayer
Withdrawn
NCT01508364 2015-01-21
NEXTAR
Bayer
Completed
NCT00126503 2015-01-15
Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney Cancer
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00352859 2014-12-30
Phase IV Randomization to On-Going Treatment to Evaluate Sustained Sorafenib
Bayer
Phase 4 Terminated
NCT00492986 2014-12-30
An Open-Label, Non-Comparative, Phase III Study of the Raf-Kinase Inhibitor BAY 43-9006 as a Subsequent to First-Line Therapy in Patients With Advanced Renal Cell Carcinoma
Bayer
Phase 3 Completed
NCT00661375 2014-12-25
BAY43-9006 Phase II Study for Renal Cell Carcinoma
Bayer
Phase 2 Completed